Following our integration into the Cruinn Diagnostics Group, this strategic partnership expands our specialized diagnostic portfolio tailored heavily for mental health care pathways. The Medimate system represents a monumental shift in how NHS trusts and psychiatric clinics can manage bipolar disorder patients undergoing lithium therapy.

By utilizing advanced lab-on-a-chip technology, the Medimate handheld “Minilab” enables clinical staff to measure both Lithium levels and kidney function (Creatinine/eGFR) simultaneously from a single drop of fingertip blood. Delivering laboratory-accurate results within minutes at the point of care, it eliminates traditional pathology turnaround delays, drastically optimizes outpatient psychiatric pathways, and enhances patient safety by flagging toxicity risks immediately.

Through this exclusive agreement, Katalyst Diagnostics will provide comprehensive end-to-end framework procurement, implementation training, technical compliance support, and product supply to our NHS and clinical partners across both territories.